Tags

Type your tag names separated by a space and hit enter

Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study.
Ter Arkh 2019; 91(2):25-31TA

Abstract

AIM

To evaluate the effectiveness of enteroprotector Rebamipide in the treatment of enteropathy with impaired membrane digestion (EIMD).

MATERIALS AND METHODS

We examined 102 patients aged 18 to 50 years (41 men and 61 women) with clinical signs of irritable bowel syndrome (n=65), functional diarrhea (n=33), and functional constipation (n=4) according to Rome IV criteria (2016). The activities of glucoamylase (GA), maltase, sucrase and lactase were determined by Dahlquist-Trinder method in duodenal biopsies obtained during esophagogastroduodenoscopy. The control group consisted of 20 healthy people aged 23-47. They showed following average enzyme activity: lactase - 42±13 ng glucose on 1 mg of tissue per minute, GA - 509±176, maltase - 1735±446, sucrase - 136±35 ng glucose on 1 mg of tissue per minute. These numbers were taken as the norm.

RESULTS

The activity of the disaccharidases was reduced in 89.2% out of 102 patients, and they were diagnosed with EIMD. Thirteen patients with EIMD were recommended to maintain the FODMAP diet and take enteroprotector Rebamipide 100 mg 3 times a day for 12 weeks. After 3 months 11 patients reported decreased or no flatulence, abdominal pain, stool disorder; 2 patients reported no change. The activity of GA increased to an average of 149±82 (by 78%, p=0.016), maltase - to 864±472 (by 131%, p=0.0019), sucrase - 63±35 (by 95%, p=0.0041) and lactase - 10±8 ng glucose on 1 mg of tissue per minute. The activity of lactase did not change.

CONCLUSION

We discovered a previously unknown phenomenon of the disaccharidases activity increase in duodenal mucosa and improved carbohydrates tolerance in the patients with EIMD taking Rebamipide in the dose 300 mg/day for 12 weeks.

Authors+Show Affiliations

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia.A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia.A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia.A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia.A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia.A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia.A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31094168

Citation

Parfenov, А I., et al. "Rebamipide Increases the Disaccharidases Activity in Patients With Enteropathy With Impaired Membrane Digestion. Pilot Study." Terapevticheskii Arkhiv, vol. 91, no. 2, 2019, pp. 25-31.
Parfenov АI, Belostotsky NI, Khomeriki SG, et al. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Ter Arkh. 2019;91(2):25-31.
Parfenov, А. I., Belostotsky, N. I., Khomeriki, S. G., Akhmadullina, O. V., Bykova, S. V., Sabelnikova, E. A., & Dbar, S. R. (2019). Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Terapevticheskii Arkhiv, 91(2), pp. 25-31. doi:10.26442/00403660.2019.02.000123.
Parfenov АI, et al. Rebamipide Increases the Disaccharidases Activity in Patients With Enteropathy With Impaired Membrane Digestion. Pilot Study. Ter Arkh. 2019 Mar 18;91(2):25-31. PubMed PMID: 31094168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. AU - Parfenov,А I, AU - Belostotsky,N I, AU - Khomeriki,S G, AU - Akhmadullina,O V, AU - Bykova,S V, AU - Sabelnikova,E A, AU - Dbar,S R, PY - 2019/5/17/entrez PY - 2019/5/17/pubmed PY - 2019/7/2/medline KW - Enteropathy with impaired membrane digestion (EIMD) KW - Rebamipid KW - disaccharidasen KW - duodenal mucosa KW - glucoamylasa KW - lactase KW - maltasa KW - sucrosa SP - 25 EP - 31 JF - Terapevticheskii arkhiv JO - Ter. Arkh. VL - 91 IS - 2 N2 - AIM: To evaluate the effectiveness of enteroprotector Rebamipide in the treatment of enteropathy with impaired membrane digestion (EIMD). MATERIALS AND METHODS: We examined 102 patients aged 18 to 50 years (41 men and 61 women) with clinical signs of irritable bowel syndrome (n=65), functional diarrhea (n=33), and functional constipation (n=4) according to Rome IV criteria (2016). The activities of glucoamylase (GA), maltase, sucrase and lactase were determined by Dahlquist-Trinder method in duodenal biopsies obtained during esophagogastroduodenoscopy. The control group consisted of 20 healthy people aged 23-47. They showed following average enzyme activity: lactase - 42±13 ng glucose on 1 mg of tissue per minute, GA - 509±176, maltase - 1735±446, sucrase - 136±35 ng glucose on 1 mg of tissue per minute. These numbers were taken as the norm. RESULTS: The activity of the disaccharidases was reduced in 89.2% out of 102 patients, and they were diagnosed with EIMD. Thirteen patients with EIMD were recommended to maintain the FODMAP diet and take enteroprotector Rebamipide 100 mg 3 times a day for 12 weeks. After 3 months 11 patients reported decreased or no flatulence, abdominal pain, stool disorder; 2 patients reported no change. The activity of GA increased to an average of 149±82 (by 78%, p=0.016), maltase - to 864±472 (by 131%, p=0.0019), sucrase - 63±35 (by 95%, p=0.0041) and lactase - 10±8 ng glucose on 1 mg of tissue per minute. The activity of lactase did not change. CONCLUSION: We discovered a previously unknown phenomenon of the disaccharidases activity increase in duodenal mucosa and improved carbohydrates tolerance in the patients with EIMD taking Rebamipide in the dose 300 mg/day for 12 weeks. SN - 0040-3660 UR - https://www.unboundmedicine.com/medline/citation/31094168/Rebamipide_increases_the_disaccharidases_activity_in_patients_with_enteropathy_with_impaired_membrane_digestion._Pilot_study L2 - https://medlineplus.gov/malabsorptionsyndromes.html DB - PRIME DP - Unbound Medicine ER -